The earnings call highlighted several strategic successes, including growth in the GLP-1 market and strong performance in HPP components. However, challenges in proprietary product revenues, contract manufacturing, and margins were significant issues that tempered the positive aspects. The company is actively addressing these challenges with strategic investments and initiatives.

Company Guidance

During the West Pharmaceutical Services, Inc. fourth quarter 2024 earnings call, guidance for fiscal year 2025 was provided, highlighting several key financial metrics. The company expects full-year 2025 net sales to be between $2.875 billion and $2.905 billion, with an organic sales growth of approximately 2% to 3%. Adjusted operating profit margin for 2025 is projected to slightly improve, driven by expansion in HPP components. They anticipate proprietary product segment organic revenues to increase, with biologics expected to grow high single digits to low double digits. The adjusted diluted EPS for 2025 is anticipated to range between $6.00 to $6.20. Capital expenditures are expected to decrease to $275 million in 2025, reflecting a return to traditional levels. Additionally, first-quarter 2025 net sales are projected between $680 million and $690 million, with adjusted EPS expected to be in the range of $1.20 to $1.25.

Strategic Initiatives Success

Executed key strategic initiatives, capitalizing on the fast-growing GLP-1 market and strong win rate on newly approved molecules, particularly in biologics.

Shareholder Returns

Returned over $560 million to shareholders through share repurchase program during the year.

Organic Sales Growth

Fourth quarter revenues increased 3.3% on an organic basis, marking a return to quarterly revenue growth.

HPP Component Growth

HPP components, the most important contributor to long-term growth, is starting to show signs of strengthening with expected mid to high single-digit growth in 2025.

Annex One Projects

Over 200 Annex One projects in various stages with customers, expected to contribute 100-150 basis point growth expansion in 2025.

---

West Pharmaceutical Services (WST) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

WST Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 24, 2025	2025 (Q1)	1.22 / -	1.56	―	―	―
Feb 13, 2025	2024 (Q4)	1.72 / 1.82	1.83	-0.55% (-0.01)
Oct 24, 2024	2024 (Q3)	1.50 / 1.85	2.16	-14.35% (-0.31)
Jul 25, 2024	2024 (Q2)	1.74 / 1.52	2.11	-27.96% (-0.59)
Apr 25, 2024	2024 (Q1)	1.27 / 1.56	1.98	-21.21% (-0.42)
Feb 15, 2024	2023 (Q4)	1.78 / 1.83	1.77	3.39% (+0.06)
Oct 26, 2023	2023 (Q3)	1.86 / 2.16	2.03	6.40% (+0.13)
Jul 27, 2023	2023 (Q2)	1.93 / 2.11	2.47	-14.57% (-0.36)
Apr 27, 2023	2023 (Q1)	1.67 / 1.98	2.3	-13.91% (-0.32)
Feb 16, 2023	2022 (Q4)	1.38 / 1.77	2.04	-13.24% (-0.27)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

WST Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 13, 2025	$322.28	$199.11	-38.22%
Oct 24, 2024	$286.07	$330.23	+15.44%
Jul 25, 2024	$323.14	$276.62	-14.40%
Apr 25, 2024	$384.98	$367.46	-4.55%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---